These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 15529212)

  • 1. [Once weekly fluoxetine, tolerability and safety according to use patterns in the psychiatric clinical practice].
    Montejo González AL; de la Gándara J; Majadas Fernández S; Vega Fernández FM; Varona A
    Actas Esp Psiquiatr; 2004; 32(5):280-6. PubMed ID: 15529212
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Switching patients from daily citalopram, paroxetine, or sertraline to once-weekly fluoxetine in the maintenance of response for depression.
    Miner CM; Brown EB; Gonzales JS; Munir R
    J Clin Psychiatry; 2002 Mar; 63(3):232-40. PubMed ID: 11926723
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The efficacy and safety of a new enteric-coated formulation of fluoxetine given once weekly during the continuation treatment of major depressive disorder.
    Schmidt ME; Fava M; Robinson JM; Judge R
    J Clin Psychiatry; 2000 Nov; 61(11):851-7. PubMed ID: 11105738
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A double-blind comparison of sertraline and fluoxetine in the treatment of major depressive episode in outpatients.
    Sechter D; Troy S; Paternetti S; Boyer P
    Eur Psychiatry; 1999 Mar; 14(1):41-8. PubMed ID: 10572324
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of weekly treatment with enteric-coated fluoxetine in patients with major depressive disorder.
    Dinan TG
    J Clin Psychiatry; 2001; 62 Suppl 22():48-52. PubMed ID: 11599649
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patient compliance with enteric-coated weekly fluoxetine during continuation treatment of major depressive disorder.
    de Klerk E
    J Clin Psychiatry; 2001; 62 Suppl 22():43-7. PubMed ID: 11599648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment approaches to major depressive disorder relapse. Part 1: dose increase.
    Schmidt ME; Fava M; Zhang S; Gonzales J; Raute NJ; Judge R
    Psychother Psychosom; 2002; 71(4):190-4. PubMed ID: 12097783
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of fluoxetine in preschool children with obsessive-compulsive disorder.
    Coskun M; Zoroglu S
    J Child Adolesc Psychopharmacol; 2009 Jun; 19(3):297-300. PubMed ID: 19519265
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Are patients who are intolerant to one serotonin selective reuptake inhibitor intolerant to another?
    Brown WA; Harrison W
    J Clin Psychiatry; 1995 Jan; 56(1):30-4. PubMed ID: 7836337
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Citalopram treatment of fluoxetine-intolerant depressed patients.
    Calabrese JR; Londborg PD; Shelton MD; Thase ME
    J Clin Psychiatry; 2003 May; 64(5):562-7. PubMed ID: 12755660
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mirtazapine: efficacy and tolerability in comparison with fluoxetine in patients with moderate to severe major depressive disorder. Mirtazapine-Fluoxetine Study Group.
    Wheatley DP; van Moffaert M; Timmerman L; Kremer CM
    J Clin Psychiatry; 1998 Jun; 59(6):306-12. PubMed ID: 9671343
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Once-weekly dosing of fluoxetine in the maintenance of remission in panic disorder.
    Emmanuel NP; Ware MR; Brawman-Mintzer O; Ballenger JC; Lydiard RB
    J Clin Psychiatry; 1999 May; 60(5):299-301. PubMed ID: 10362436
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment approaches to major depressive disorder relapse. Part 2: reinitiation of antidepressant treatment.
    Fava M; Schmidt ME; Zhang S; Gonzales J; Raute NJ; Judge R
    Psychother Psychosom; 2002; 71(4):195-9. PubMed ID: 12097784
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized, double-blind comparison of venlafaxine and fluoxetine in outpatients with major depression.
    Costa e Silva J
    J Clin Psychiatry; 1998 Jul; 59(7):352-7. PubMed ID: 9714263
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fluoxetine versus placebo in posttraumatic stress disorder.
    Martenyi F; Brown EB; Zhang H; Prakash A; Koke SC
    J Clin Psychiatry; 2002 Mar; 63(3):199-206. PubMed ID: 11926718
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A 24-week open-label extension study of olanzapine-fluoxetine combination and olanzapine monotherapy in the treatment of bipolar depression.
    Corya SA; Perlis RH; Keck PE; Lin DY; Case MG; Williamson DJ; Tohen MF
    J Clin Psychiatry; 2006 May; 67(5):798-806. PubMed ID: 16841630
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fluoxetine treatment of children with selective mutism: an open trial.
    Dummit ES; Klein RG; Tancer NK; Asche B; Martin J
    J Am Acad Child Adolesc Psychiatry; 1996 May; 35(5):615-21. PubMed ID: 8935208
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Superior antidepressant efficacy results of agomelatine versus fluoxetine in severe MDD patients: a randomized, double-blind study.
    Hale A; Corral RM; Mencacci C; Ruiz JS; Severo CA; Gentil V
    Int Clin Psychopharmacol; 2010 Nov; 25(6):305-14. PubMed ID: 20856123
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in adverse events reported by patients during 6 months of fluoxetine therapy.
    Zajecka J; Amsterdam JD; Quitkin FM; Reimherr FW; Rosenbaum JF; Tamura RN; Sundell KL; Michelson D; Beasley CM
    J Clin Psychiatry; 1999 Jun; 60(6):389-94. PubMed ID: 10401918
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravenous administration of adenosine triphosphate and phosphocreatine combined with fluoxetine in major depressive disorder: protocol for a randomized, double-blind, placebo-controlled pilot study.
    Chen Y; Cao X; Zang W; Tan S; Ou CQ; Shen X; Gao T; Zhao L
    Trials; 2019 Jan; 20(1):34. PubMed ID: 30626424
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.